Chicago, IL (PRWEB) January 07, 2014
For 2014, the prescription drug safety advocates at DrugRisk.com have launched a new patient resource center for women who have taken the birth control pills Yaz or Yasmin. The site will offer the latest research, warnings and legal news on contraceptives like Yaz that use the hormone drospirenone.
The Yaz Center is a free resource from DrugRisk, an effort to provide women with updated information on the risks and benefits of prescription birth control. With data on Yaz, Yasmin, NuvaRing and Mirena IUDs, patients can find out if others are experiencing similar side effects and decide if they need legal advice.
DrugRisk has compiled warnings from health experts such as the British Medical Journal** and FDA*** that birth control pills containing the hormone drospirenone, like Yaz and Yasmin, can increase the risk of blood clots.
Due to the number of patients who’ve filed a Yaz lawsuit alleging side effects, cases were relocated to a special federal court in Illinois (Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100, Southern District Illinois)).
The latest court records obtained by DrugRisk show 9,826 Yaz claims were pending as of December 16*.
The new resource center has also compiled the latest news on Yaz settlements. Bayer has spent nearly $1.575 billion so far to settle around 7,660 Yaz lawsuits alleging blood clot injuries like pulmonary embolism or deep vein thrombosis (DVT)****.
Anyone who suffered a blood clot, DVT, stroke or pulmonary embolism after taking Yaz or Yasmin is urged to visit the DrugRisk Yaz Center or speak with a lawyer about their legal options.
Due to the specialized nature of federal drug injury litigation, DrugRisk only recommends lawyers who have already settled Yaz lawsuits.
For more information on the research, side effects and litigation news related to Yaz and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.
*Judicial Panel on Multidistrict Litigation, 12/16/13; jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-December-16-2013.pdf
**BMJ, 10/25/11; ncbi.nlm.nih.gov/pubmed/22027398
***FDA, 10/27/11, fda.gov/downloads/Drugs/DrugSafety/UCM277384.pdf
****Bayer Stockholder’s Newsletter, Explanatory Notes; Legal Risks, 10/31/13; stockholders-newsletter-q3-2013.bayer.com/en/explanatory-notes.aspx